<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35143900</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-2596</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>1869</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biochimica et biophysica acta. Molecular cell research</Title>
          <ISOAbbreviation>Biochim Biophys Acta Mol Cell Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Galectin-3 S-glutathionylation regulates its effect on adipocyte insulin signaling.</ArticleTitle>
        <Pagination>
          <StartPage>119234</StartPage>
          <MedlinePgn>119234</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbamcr.2022.119234</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0167-4889(22)00025-8</ELocationID>
        <Abstract>
          <AbstractText>Protein-S-glutathionylation promotes redox signaling in physiological and oxidative distress conditions. Galectin-3 (Gal-3) promotes insulin resistance by down-regulating adipocyte insulin signaling, however, its S-glutathionylation and significance is not known. In this context, we report reversible S-glutathionylation of Gal-3. Site-directed mutagenesis established Gal-3 Cys187 as the putative S-glutathionylation site. Glutathionylated Gal-3 prevents Gal-3(WT)-Insulin Receptor interaction and facilitates insulin-induced murine adipocyte p-IRS1(tyr895) and p-AKT(ser473) signaling and glucose uptake in a Gal-3 Cys187 glutathionylation dependent manner in murine adipocytes, as assessed by Western blotting and 2-NBDG uptake assay respectively. Pre-glutathionylated Gal-3 at Cys187 resisted irreversible oxidation by H<sub>2</sub>O<sub>2</sub>. M2 macrophages showed enhanced Gal-3 S-glutathionylation when compared to M1 phenotype. Serum and stromal vascular fraction (SVF) isolated from control mice showed increased Gal-3 S-glutathionylation as compared to db/db mice. A significant increase in Gal-3 S-glutathionylation was observed in metformin-treated db/db mice when compared to db/db mice alone. Similar to murine, enhanced Gal-3 S-glutathionylation is observed in primary human monocyte derived M2 macrophages when compared to the M1 macrophage phenotype and Gal-3 regulates primary human adipocyte insulin signaling in a glutathionylation dependent manner. Collectively, we identified Gal-3 S-glutathionylation as a protective phenomenon, which relieves its inhibitory effect on adipocyte insulin signaling.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Maurya</LastName>
            <ForeName>Mohita</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow 226031, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jaiswal</LastName>
            <ForeName>Anant</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow 226031, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gupta</LastName>
            <ForeName>Sanchita</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow 226031, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ali</LastName>
            <ForeName>Wahid</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>King George's Medical University, Lucknow 226003, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gaikwad</LastName>
            <ForeName>Anil Nilkanth</ForeName>
            <Initials>AN</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow 226031, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dikshit</LastName>
            <ForeName>Madhu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow 226031, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barthwal</LastName>
            <ForeName>Manoj Kumar</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad - 201002, India. Electronic address: manojbarthwal@cdri.res.in.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Biochim Biophys Acta Mol Cell Res</MedlineTA>
        <NlmUniqueID>101731731</NlmUniqueID>
        <ISSNLinking>0167-4889</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037502">Galectin 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BBX060AN9V</RegistryNumber>
          <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017667" MajorTopicYN="N">Adipocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037502" MajorTopicYN="Y">Galectin 3</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="Y">Insulin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Galectin-3</Keyword>
        <Keyword MajorTopicYN="Y">Insulin resistance</Keyword>
        <Keyword MajorTopicYN="Y">Macrophage</Keyword>
        <Keyword MajorTopicYN="Y">Reactive oxygen species</Keyword>
        <Keyword MajorTopicYN="Y">S-glutathionylation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>20</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35143900</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbamcr.2022.119234</ArticleId>
        <ArticleId IdType="pii">S0167-4889(22)00025-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
